Patents by Inventor Masaki Terabe
Masaki Terabe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11266726Abstract: Recombinant adenoviruses expressing the extracellular (EC) and transmembrane (TM) domains of human HER2 (HER2ECTM) are described. The recombinant adenoviruses express a chimeric fiber protein having the adenovirus type 35 (Ad5) shaft and knob domains, which facilitates transduction of human dendritic cells by the recombinant HER2ECTM expressing adenovirus. Compositions that include dendritic cells transduced by the recombinant adenovirus and their use for treating HER-positive tumors is described.Type: GrantFiled: October 31, 2016Date of Patent: March 8, 2022Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Baylor College of MedicineInventors: Lauren V. Wood, Brenda D. Roberson, Jay A. Berzofsky, John C. Morris, Jason C. Steel, Masaki Terabe, Malcolm K. Brenner
-
Publication number: 20210023110Abstract: Disclosed is a compound of the formula (I) or (II): wherein a f are as described herein. The compounds are useful in the activation of Type II NKT cells and in treating cancer.Type: ApplicationFiled: March 25, 2019Publication date: January 28, 2021Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, University of ConnecticutInventors: Lise H. Pasquet, Jay A. Berzofsky, Amy R. Howell, Masaki Terabe, Kaddy Camara, Stewart K. Richardson
-
Patent number: 10286050Abstract: Immunogenic T cell receptor ? alternate reading frame protein (TARP) peptide compositions that include multiple epitopes of the TARP protein are described. The disclosed compositions can be used for the treatment of TARP-expressing cancers, such as prostate cancer, breast cancer and mesothelioma. In some embodiments, the TARP peptide compositions disclosed herein include sets of overlapping TARP peptides that each have a length of about 15 to about 25 amino acids, and comprise about 5 to about 15 amino acids that are identical to at least another overlapping peptide in the set. In particular examples, the combination of the overlapping TARP peptides in the set encompasses the complete amino acid sequence of human TARP. The multi-epitope peptide compositions described herein include both CD4 and CD8 epitopes, a feature that is important for eliciting CD4+ T cell and CD8+ T cell, as well as humoral, immune responses.Type: GrantFiled: December 12, 2014Date of Patent: May 14, 2019Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Lauren V. Wood, Jay A. Berzofsky, Brenda D. Roberson, Masaki Terabe
-
Publication number: 20180344828Abstract: Recombinant adenoviruses expressing the extracellular (EC) and transmembrane (TM) domains of human HER2 (HER2ECTM) are described. The recombinant adenoviruses express a chimeric fiber protein having the adenovirus type 35 (Ad5) shaft and knob domains, which facilitates transduction of human dendritic cells by the recombinant HER2ECTM expressing adenovirus. Compositions that include dendritic cells transduced by the recombinant adenovirus and their use for treating HER-positive tumors is described.Type: ApplicationFiled: October 31, 2016Publication date: December 6, 2018Applicants: The U.S.A., as represented by the Secretary, Department of Health and Human Services, Baylor College of MedicineInventors: Lauren V. Wood, Brenda D. Roberson, Jay A. Berzofsky, John C. Morris, Jason C. Steel, Masaki Terabe, Malcolm K. Brenner
-
Patent number: 9517243Abstract: ?-mannosylceramides or salts or solvates thereof in a pharmaceutically acceptable carrier, for use as a Type I NKT cell agonist in conjunction with a therapeutically effective amount of ?-galactosylceramide or a salt or a solvate thereof, and/or at least one or more T-cell co-stimulatory molecules, disclosed. Compositions comprising ?-mannosylceramide, as well as methods of treatment of tumors are also provided.Type: GrantFiled: October 9, 2015Date of Patent: December 13, 2016Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The University of Birmingham of EdgbastonInventors: Jay A. Berzofsky, Jessica J. O'Konek, Masaki Terabe, Petr A. Illarionov, Gurdyal S. Besra
-
Publication number: 20160310585Abstract: Immunogenic T cell receptor ? alternate reading frame protein (TARP) peptide compositions that include multiple epitopes of the TARP protein are described. The disclosed compositions can be used for the treatment of TARP-expressing cancers, such as prostate cancer, breast cancer and mesothelioma. In some embodiments, the TARP peptide compositions disclosed herein include sets of overlapping TARP peptides that each have a length of about 15 to about 25 amino acids, and comprise about 5 to about 15 amino acids that are identical to at least another overlapping peptide in the set. In particular examples, the combination of the overlapping TARP peptides in the set encompasses the complete amino acid sequence of human TARP. The multi-epitope peptide compositions described herein include both CD4 and CD8 epitopes, a feature that is important for eliciting CD4+ T cell and CD8+ T cell, as well as humoral, immune responses.Type: ApplicationFiled: December 12, 2014Publication date: October 27, 2016Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventors: Lauren V. Wood, Jay A. Berzofsky, Brenda D. Roberson, Masaki Terabe
-
Patent number: 9394352Abstract: POTE has recently been identified as a tumor antigen expressed in a variety of human cancers, including colon, ovarian, breast, prostate, lung and pancreatic cancer. Described herein are immunogenic POTE polypeptides, including modified POTE polypeptides, that bind MHC class I molecules. The immunogenic POTE polypeptides are capable of inducing an immune response against POTE-expressing tumor cells. Thus, provided herein is a method of eliciting an immune response in a subject, such as a subject having a type of cancer that expresses POTE.Type: GrantFiled: September 25, 2014Date of Patent: July 19, 2016Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Jay A. Berzofsky, Yi-Hsiang Huang, Masaki Terabe, Ira H. Pastan
-
Publication number: 20160101123Abstract: ?-mannosylceramides or salts or solvates thereof in a pharmaceutically acceptable carrier, for use as a Type I NKT cell agonist in conjunction with a therapeutically effective amount of ?-galactosylceramide or a salt or a solvate thereof, and/or at least one or more T-cell co-stimulatory molecules, disclosed. Compositions comprising ?-mannosylceramide, as well as methods of treatment of tumors are also provided.Type: ApplicationFiled: October 9, 2015Publication date: April 14, 2016Inventors: Jay A . Berzofsky, Jessica J. O'Konek, Masaki Terabe, Petr A. Illarionov, Gurdyal S. Besra
-
Patent number: 9168291Abstract: ?-mannosylceramides or salts or solvates thereof in a pharmaceutically acceptable carrier, for use as a Type I NKT cell agonist in conjunction with a therapeutically effective amount of ?-galactosylceramide or a salt or a solvate thereof, and/or at least one or more T-cell co-stimulatory molecules, disclosed. Compositions comprising ?-mannosylceramide, as well as methods of treatment of tumors are also provided.Type: GrantFiled: August 7, 2014Date of Patent: October 27, 2015Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The University of BirminghamInventors: Jay A. Berzofsky, Jessica J. O'Konek, Masaki Terabe, Petr A. Illarionov, Gurdyal S. Besra
-
Publication number: 20150010590Abstract: POTE has recently been identified as a tumor antigen expressed in a variety of human cancers, including colon, ovarian, breast, prostate, lung and pancreatic cancer. Described herein are immunogenic POTE polypeptides, including modified POTE polypeptides, that bind MHC class I molecules. The immunogenic POTE polypeptides are capable of inducing an immune response against POTE-expressing tumor cells. Thus, provided herein is a method of eliciting an immune response in a subject, such as a subject having a type of cancer that expresses POTE.Type: ApplicationFiled: September 25, 2014Publication date: January 8, 2015Inventors: Jay A. Berzofsky, Yi-Hsiang Huang, Masaki Terabe, Ira H. Pastan
-
Publication number: 20140348786Abstract: ?-mannosylceramides or salts or solvates thereof in a pharmaceutically acceptable carrier, for use as a Type I NKT cell agonist in conjunction with a therapeutically effective amount of ?-galactosylceramide or a salt or a solvate thereof, and/or at least one or more T-cell co-stimulatory molecules, disclosed. Compositions comprising ?-mannosylceramide, as well as methods of treatment of tumors are also provided.Type: ApplicationFiled: August 7, 2014Publication date: November 27, 2014Inventors: Jay A. Berzofsky, Jessica J. O'Konek, Masaki Terabe, Petr A. Illarionov, Gurdyal S. Besra
-
Patent number: 8871902Abstract: POTE has recently been identified as a tumor antigen expressed in a variety of human cancers, including colon, ovarian, breast, prostate, lung and pancreatic cancer. Described herein are immunogenic POTE polypeptides, including modified POTE polypeptides, that bind MHC class I molecules. The immunogenic POTE polypeptides are capable of inducing an immune response against POTE-expressing tumor cells. Thus, provided herein is a method of eliciting an immune response in a subject, such as a subject having a type of cancer that expresses POTE.Type: GrantFiled: September 11, 2012Date of Patent: October 28, 2014Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Jay A. Berzofsky, Yi-Hsiang Huang, Masaki Terabe, Ira H. Pastan
-
Patent number: 8835613Abstract: ?-mannosylceramides or salts or solvates thereof in a pharmaceutically acceptable carrier, for use as a Type I NKT cell agonist in conjunction with a therapeutically effective amount of ?-galactosylceramide or a salt or a solvate thereof, and/or at least one or more T-cell co-stimulatory molecules, disclosed. Compositions comprising ?-mannosylceramide, as well as methods of treatment of tumors are also provided.Type: GrantFiled: March 11, 2011Date of Patent: September 16, 2014Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The University of Birmingham, of EdgbastonInventors: Jay A. Berzofsky, Jessica J. O'Konek, Masaki Terabe, Petr Illarionov, Gurdyal S. Besra
-
Publication number: 20130171178Abstract: XAGE-1 is a gene expressed in a number of important human cancers, including prostate cancer, lung cancer, breast cancer, ovarian cancer, glioblastoma, pancreatic cancer, and melanoma. It has now been discovered that peptides of fifty or fewer amino acids comprising the sequence X1X2X3PSAPSPX4 (SEQ ID NO:5), where X1 is any amino acid and is preferably G or Y; X2 is selected from the group consisting of L, M, A, I, V, and T, with L and M being preferred; X3 is a hydrophobic residue, M or A; and X4 is V, M, L, A, I, or T, and is preferably V, bind to the HLA-A2 MHC class I molecule, and can be used to raise immune responses to XAGE-1-expressing cancers. In some embodiments, the P at position 7, the S at position 8, or the P at position 9, can be omitted to create a 9 amino acid peptide.Type: ApplicationFiled: December 13, 2004Publication date: July 4, 2013Applicant: THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICESInventors: Jay A. Berzofsky, Ira H. Pastan, Masaki Terabe
-
Publication number: 20130039936Abstract: POTE has recently been identified as a tumor antigen expressed in a variety of human cancers, including colon, ovarian, breast, prostate, lung and pancreatic cancer. Described herein are immunogenic POTE polypeptides, including modified POTE polypeptides, that bind MHC class I molecules. The immunogenic POTE polypeptides are capable of inducing an immune response against POTE-expressing tumor cells. Thus, provided herein is a method of eliciting an immune response in a subject, such as a subject having a type of cancer that expresses POTE.Type: ApplicationFiled: September 11, 2012Publication date: February 14, 2013Inventors: Jay A. Berzofsky, Yi-Hsiang Huang, Masaki Terabe, Ira H. Pastan
-
Publication number: 20130039886Abstract: ?-mannosylceramides or salts or solvates thereof in a pharmaceutically acceptable carrier, for use as a Type I NKT cell agonist in conjunction with a therapeutically effective amount of ?-galactosylceramide or a salt or a solvate thereof, and/or at least one or more T-cell co-stimulatory molecules, disclosed. Compositions comprising ?-mannosylceramide, as well as methods of treatment of tumors are also provided.Type: ApplicationFiled: March 11, 2011Publication date: February 14, 2013Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Serv, The University of Birmingham, of EdgbastonInventors: Jay A. Berzofsky, Jessica J. O'Konek, Masaki Terabe, Petr Illarionov, Gurdyal S. Besra
-
Publication number: 20110268749Abstract: Disclosed herein are compositions and methods for treating or preventing cancer involving the use of a TNF-alpha antagonist, an IL-13R?2 antagonist, and/or a AP-I antagonist.Type: ApplicationFiled: July 31, 2008Publication date: November 3, 2011Applicant: The Government of the US as Represented by the Secretary Department of Health and Human ServicesInventors: Warren Strober, Jay A. Berzofsky, Stefan Fichtner-Feigl, Atsushi Kitani, Ivan J. Fuss, Masaki Terabe, Peter Mannon
-
Publication number: 20080267964Abstract: Methods are provided herein for synergistically affecting tumor growth in a subject, involving the administration to the subject of an agent that blocks the TGF-? signaling pathway in combination with an immunogenic agent. The agent that blocks the TGF-? signaling pathway is believed to inhibit the immunosuppressive effects of TGF-?, while the immunogenic agent is believed to enhance an immune response. Surprisingly, the combination of such elements produces a synergistic effect. In one embodiment, the administration of the 1D11.16 anti-TGF-? antibody in combination with the human papilloma virus E7(49-57) peptide enhances tumor regression and tumor-specific CTL response in the subject. In another embodiment, the administration of the 1D11.16 anti-TGF-? antibody in combination with irradiated CT26 cells enhances tumor regression in the subject.Type: ApplicationFiled: February 16, 2006Publication date: October 30, 2008Inventors: Masaki Terabe, Shun Takaku, Jay A. Berzofsky
-
Publication number: 20060057145Abstract: Methods are provided herein to prevent a tumor recurrence in a subject, involving administering to the subject an agent that blocks the TGF-? signaling pathway. In one embodiment, the agent inhibits the immunosuppressive effects of TGF-?. Also provided is a method of enhancing an immune respond in a subject to inhibit recurrence of a tumor by administering an agent which blocks the TGF-? signaling pathway. A method of enhancing the activity of an immune cell to inhibit recurrence of a tumor by contacting a TGF-? receptor-expressing cell with an agent which blocks the TGF-? signaling pathway is also provided, as are methods of screening for an agent that inhibits or measurably reduces the recurrence of a tumor.Type: ApplicationFiled: October 24, 2003Publication date: March 16, 2006Applicant: GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTHInventors: Jay Berzofsky, Masaki Terabe, So Matsui